The 20 Patients’ Baseline Clinical Characteristics
| Characteristic | Data |
| Mean age ± SD (y) | 67 ± 7 |
| Male (n) | 11 (55%) |
| Diabetes (n) | 4 (20%) |
| Hyperlipidemia (n) | 5 (25%) |
| Hypertension (n) | 12 (60%) |
| Tobacco use (n) | 6 (30%) |
| Family history of coronary artery disease (n) | 3 (15%) |
| Serum biomarkers | |
| Total cholesterol (mg/dL) | 162 (135–189) |
| High-density lipoprotein (mg/dL) | 43 (38–46) |
| Low-density lipoprotein (mg/dL) | 93 (71–107) |
| Triglyceride (mg/dL) | 121 (86–140) |
| Creatine (mg/dL) | 0.8 (0.7–0.9) |
| Medications | |
| Aspirin (n) | 13 (65%) |
| Statin (n) | 6 (30%) |
| ACEI/ARB (n) | 6 (30%) |
| β-blocker (n) | 7 (35%) |
| Leading clinical indication for CTA | |
| Chest pain (n) | 15 (75%) |
| Dyspnea (n) | 3 (15%) |
| Risk assessment (asymptomatic patient) (n) | 2 (10%) |
| Coronary CTA | |
| Segment involvement score | 6 (3–8) |
| Multivessel disease (n) | 6 (30%) |
| Coronary calcium score | 312 (50–770) |
ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
Qualitative data are expressed as number and percentage; continuous data, except for age, are expressed as median and interquartile range.